Phenylalanine metabolism in uremic and normal man

Area of Science:

• Biochemistry
• Nephrology
• Metabolic Disorders

Background:

• Phenylalanine and tyrosine metabolism are crucial for normal physiological function.
• Kidney disease, including chronic uremia and hemodialysis, can significantly impact metabolic pathways.

Purpose of the Study:

• To evaluate phenylalanine and tyrosine metabolism in individuals with chronic uremia and those undergoing hemodialysis.
• To compare metabolic profiles with healthy controls following a phenylalanine load.

Main Methods:

• Measurement of plasma and urinary phenylalanine, tyrosine, and 13 acidic metabolites.
• Administration of a phenylalanine load (100 mg/kg) and L-[14C]-phenylalanine tracer.
• Analysis of plasma metabolite concentrations and 14CO2 expiration over 24 hours.

Main Results:

• Uremic and dialysis patients exhibited higher and more prolonged plasma phenylalanine levels post-load, with slower tyrosine increases.
• Elevated plasma levels of phenyllactic acid, p-hydroxyphenylacetic acid, and p-hydroxybenzoic acid were observed in uremic and dialysis groups.
• Dialysis patients showed unique detection of plasma phenylpyruvic acid (PPA) and mandelic acid, with altered urinary metabolite concentrations.

Conclusions:

• Data suggest a mild impairment in phenylalanine hydroxylation in patients with kidney disease.
• Despite metabolic alterations, significant changes in plasma or urinary metabolites after a phenylalanine load were not consistently observed.